



Clinical trial results:

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease

Summary

EudraCT number	2018-003337-15
Trial protocol	HU SK ES
Global end of trial date	06 June 2024

Results information

Result version number	v1 (current)
This version publication date	20 April 2025
First version publication date	20 April 2025

Trial information

Trial identification

Sponsor protocol code	CLR_18_06
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03655236
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Sun Pharma Advanced Research Company Limited (SPARC)
Sponsor organisation address	17/B, Mahal Industrial Estate, Mahakali Caves Road, Mumbai, India, 400093
Public contact	Orest Hurko, Sun Pharma Advanced Research Company Limited (SPARC), Orest.Hurko@sparcmail.com
Scientific contact	Orest Hurko, Sun Pharma Advanced Research Company Limited (SPARC), Orest.Hurko@sparcmail.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 June 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	08 April 2024
Global end of trial reached?	Yes
Global end of trial date	06 June 2024
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To determine if K0706 reduces the rate of progression of early-stage Parkinson's disease (PD) versus placebo over 40 weeks, as assessed by the MDS-UPDRS (Movement Disorder Society – Unified Parkinson's Disease Rating Scale) Part III (motor examination) total score.

Protection of trial subjects:

The trial and site activities were monitored according to the ICH-GCP guidelines considering every aspect of the trial, ensuring that the rights, safety and well-being of patients are protected and consistent with the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 February 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	India: 89
Country: Number of subjects enrolled	United States: 221
Country: Number of subjects enrolled	Poland: 80
Country: Number of subjects enrolled	Slovakia: 21
Country: Number of subjects enrolled	Spain: 85
Country: Number of subjects enrolled	Hungary: 17
Worldwide total number of subjects	513
EEA total number of subjects	203

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	241
From 65 to 84 years	266
85 years and over	6

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects aged ≥ 50 years in whom an initial diagnosis of PD had been made within three years of the Screening visit, who score on a modified Hoehn and Yahr stage ≤ 2 and who are not on any dopaminergic treatment other than MAO-B inhibitors will be eligible for screening.

Period 1

Period 1 title	Subject Disposition in Part 1 Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	K0706, low dose

Arm description:

Part 1; low dose K0706

Arm type	Experimental
Investigational medicinal product name	K0706
Investigational medicinal product code	
Other name	Vodobatinib
Pharmaceutical forms	Capsule, Powder for oral suspension in sachet
Routes of administration	Oral use

Dosage and administration details:

The study drug will be administered in the form of a 96 mg capsule or 192 mg powder; subjects will be instructed to take the study drug orally once daily. They should not eat food two hours prior and at least one (but ideally two) hour after dosing. For the powder formulation, the entire contents of one sachet are to be added to a glass of water (at least 4 oz. [120 mL]), mixed uniformly using a spoon or other stirrer, and ingested promptly. Any residual powder remaining in the glass or on the stirrer should be mixed with additional water and consumed to ensure ingestion of the total dose.

Arm title	K0706, high dose
------------------	------------------

Arm description:

Part 1; high dose K0706

Arm type	Experimental
Investigational medicinal product name	K0706
Investigational medicinal product code	
Other name	Vodobatinib
Pharmaceutical forms	Capsule, Powder for oral suspension in sachet
Routes of administration	Oral use

Dosage and administration details:

The study drug will be administered in the form of a 96 mg capsule or 192 mg powder; subjects will be instructed to take the study drug orally once daily. They should not eat food two hours prior and at least one (but ideally two) hour after dosing. For the powder formulation, the entire contents of one sachet are to be added to a glass of water (at least 4 oz. [120 mL]), mixed uniformly using a spoon or other stirrer, and ingested promptly. Any residual powder remaining in the glass or on the stirrer should be mixed with additional water and consumed to ensure ingestion of the total dose.

Arm title	Placebo
------------------	---------

Arm description:

Part 1; placebo

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, Powder for oral suspension in sachet
Routes of administration	Oral use

Dosage and administration details:

The study drug will be administered in the form of a 96 mg capsule or 192 mg powder; subjects will be instructed to take the study drug orally once daily. They should not eat food two hours prior and at least one (but ideally two) hour after dosing. For the powder formulation, the entire contents of one sachet are to be added to a glass of water (at least 4 oz. [120 mL]), mixed uniformly using a spoon or other stirrer, and ingested promptly. Any residual powder remaining in the glass or on the stirrer should be mixed with additional water and consumed to ensure ingestion of the total dose.

The placebo formulation will contain the same excipients as that of the K0706 formulation and match the K0706 formulation in shape, size, and color.

Number of subjects in period 1	K0706, low dose	K0706, high dose	Placebo
Started	171	174	168
Completed	114	66	120
Not completed	57	108	48
Adverse event, serious fatal	1	-	-
Consent withdrawn by subject	11	16	6
Physician decision	-	3	2
Study terminated by Sponsor	12	8	13
Adverse event, non-fatal	25	55	12
Requires prohibited medication	4	5	3
Poor compliance	-	2	-
Not specified	-	2	2
Withdrawal by Subject	-	5	3
Lost to follow-up	1	3	2
Parkinson's disease progression	2	8	5
Protocol deviation	1	1	-

Period 2

Period 2 title	Subject Disposition in Part 2 Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Assessor

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	K0706, low dose
Arm description: Part 2; K0706 low dose	
Arm type	Experimental
Investigational medicinal product name	K0706
Investigational medicinal product code	
Other name	Vodobatinib
Pharmaceutical forms	Capsule, Powder for oral suspension in sachet
Routes of administration	Oral use

Dosage and administration details:

The study drug will be administered in the form of a 96 mg capsule or 192 mg powder; subjects will be instructed to take the study drug orally once daily. They should not eat food two hours prior and at least one (but ideally two) hour after dosing. For the powder formulation, the entire contents of one sachet are to be added to a glass of water (at least 4 oz. [120 mL]), mixed uniformly using a spoon or other stirrer, and ingested promptly. Any residual powder remaining in the glass or on the stirrer should be mixed with additional water and consumed to ensure ingestion of the total dose.

Arm title	K0706, high dose
Arm description: Part 2, high dose; includes subjects from the prior Placebo arm, who were transitioned to K0706 High Dose	
Arm type	Experimental
Investigational medicinal product name	K0706
Investigational medicinal product code	
Other name	Vodobatinib
Pharmaceutical forms	Capsule, Powder for oral suspension in sachet
Routes of administration	Oral use

Dosage and administration details:

The study drug will be administered in the form of a 96 mg capsule or 192 mg powder; subjects will be instructed to take the study drug orally once daily. They should not eat food two hours prior and at least one (but ideally two) hour after dosing. For the powder formulation, the entire contents of one sachet are to be added to a glass of water (at least 4 oz. [120 mL]), mixed uniformly using a spoon or other stirrer, and ingested promptly. Any residual powder remaining in the glass or on the stirrer should be mixed with additional water and consumed to ensure ingestion of the total dose.

Arm title	Placebo
Arm description: Part 2 placebo arm	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, Powder for oral suspension in sachet
Routes of administration	Oral use

Dosage and administration details:

The study drug will be administered in the form of a 96 mg capsule or 192 mg powder; subjects will be instructed to take the study drug orally once daily. They should not eat food two hours prior and at least one (but ideally two) hour after dosing. For the powder formulation, the entire contents of one sachet are to be added to a glass of water (at least 4 oz. [120 mL]), mixed uniformly using a spoon or other stirrer, and ingested promptly. Any residual powder remaining in the glass or on the stirrer should be mixed with additional water and consumed to ensure ingestion of the total dose. The placebo formulation will contain the same excipients as that of the K0706 formulation and match the K0706 formulation in shape, size, and color.

Number of subjects in period 2 ^{[1][2]}	K0706, low dose	K0706, high dose	Placebo
Started	72	21	77
Completed	36	29	27
Not completed	36	19	50
Consent withdrawn by subject	5	1	12
Study terminated by Sponsor	18	11	13
Adverse event, non-fatal	2	5	12
Requires prohibited medication	3	1	5
Not specified	1	-	-
Withdrawal by Subject	1	1	2
Lost to follow-up	1	-	-
Parkinson's disease progression	4	-	2
Protocol deviation	1	-	4
Joined	0	27	0
Transferred in from other group/arm	-	27	-

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Subjects who had been randomized to placebo in Part 1 will be rolled over to a high dose K0706 at Week 40.

[2] - The number of subjects transferring in and out of the arms in the period are not the same. It is expected the net number of transfers in and out of the arms in a period, will be zero.

Justification: Subjects who had been randomized to placebo in Part 1 will be rolled over to a high dose K0706 at Week 40.

Baseline characteristics

Reporting groups

Reporting group title	Subject Disposition in Part 1 Period
-----------------------	--------------------------------------

Reporting group description: -

Reporting group values	Subject Disposition in Part 1 Period	Total	
Number of subjects	513	513	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	241	241	
From 65-84 years	266	266	
85 years and over	6	6	
Age continuous			
Units: years			
arithmetic mean	65.0		
standard deviation	± 8.05	-	
Gender categorical			
Units: Subjects			
Female	179	179	
Male	334	334	

End points

End points reporting groups

Reporting group title	K0706, low dose
Reporting group description: Part 1; low dose K0706	
Reporting group title	K0706, high dose
Reporting group description: Part 1; high dose K0706	
Reporting group title	Placebo
Reporting group description: Part 1; placebo	
Reporting group title	K0706, low dose
Reporting group description: Part 2; K0706 low dose	
Reporting group title	K0706, high dose
Reporting group description: Part 2, high dose; includes subjects from the prior Placebo arm, who were transitioned to K0706 High Dose	
Reporting group title	Placebo
Reporting group description: Part 2 placebo arm	

Primary: Change From Baseline to Week 40 in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Total Score.

End point title	Change From Baseline to Week 40 in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Total Score. ^[1]
-----------------	--

End point description:

End point type	Primary
End point timeframe: Week 40	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Calculated based on MDS-UPDRS.

End point values	K0706, low dose	K0706, high dose	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	164	162	161	
Units: Score on a scale				
arithmetic mean (standard deviation)	1.5 (± 8.77)	1.0 (± 7.58)	-1.0 (± 8.13)	

Statistical analyses

No statistical analyses for this end point

Primary: Incidence of Treatment-emergent Adverse Events

End point title Incidence of Treatment-emergent Adverse Events^[2]

End point description:

End point type Primary

End point timeframe:

Week 80

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Calculated based on the number of study participants.

End point values	K0706, low dose	K0706, high dose	Placebo	K0706, low dose
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	171	173	167	72
Units: Participants	131	150	124	37

End point values	K0706, high dose	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	40	77		
Units: Participants	24	61		

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change From Baseline to Week 40 in the Sum of the MDS-UPDRS Parts II and III Total Scores Part 2: Change From Week 40 to Week 76 in the Sum of the MDS-UPDRS Part III Scores

End point title Part 1: Change From Baseline to Week 40 in the Sum of the MDS-UPDRS Parts II and III Total Scores Part 2: Change From Week 40 to Week 76 in the Sum of the MDS-UPDRS Part III Scores

End point description:

End point type Secondary

End point timeframe:

Part 1: Week 40

End point values	K0706, low dose	K0706, high dose	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	164	162	161	
Units: Score on a scale				
arithmetic mean (standard deviation)	2.6 (± 10.83)	2.7 (± 9.72)	-0.6 (± 9.53)	

Statistical analyses

No statistical analyses for this end point

Secondary: Time From First Dose in Part 1 to Initiation of Symptomatic PD Medications

End point title	Time From First Dose in Part 1 to Initiation of Symptomatic PD Medications
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Part 1: Week 40 and Part 2: Week 80

End point values	K0706, low dose	K0706, high dose	Placebo	K0706, low dose
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	164 ^[3]	162 ^[4]	161 ^[5]	70 ^[6]
Units: Participants	149	129	144	60

Notes:

[3] - Part 1

[4] - Part 1

[5] - Part 1

[6] - Part 2

End point values	K0706, high dose	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	35 ^[7]	71 ^[8]		
Units: Participants	33	57		

Notes:

[7] - Part 2

[8] - Part 2

Statistical analyses

No statistical analyses for this end point

Secondary: Change in Health Related Quality of Life as Measured by the European Quality of Life Questionnaire 5 Level Version

End point title	Change in Health Related Quality of Life as Measured by the European Quality of Life Questionnaire 5 Level Version
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Week 40

End point values	K0706, low dose	K0706, high dose	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	89	56	97	
Units: Score on a scale				
arithmetic mean (standard deviation)	-0.0419 (\pm 0.11060)	-0.0531 (\pm 0.16289)	-0.0140 (\pm 0.10787)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change in Clinician Global Impression Severity

End point title	Change in Clinician Global Impression Severity
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Week 40

End point values	K0706, low dose	K0706, high dose	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	104	61	103	
Units: Score on a scale				
arithmetic mean (standard deviation)	0.2 (\pm 0.68)	0.0 (\pm 0.74)	0.2 (\pm 0.91)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change in the Scales for Outcomes in Parkinson's Disease - Autonomic Questionnaire - Page

End point title	Change in the Scales for Outcomes in Parkinson's Disease - Autonomic Questionnaire - Page
-----------------	---

End point description:	
Data Not Reported	
End point type	Secondary
End point timeframe:	
Week 40	

End point values	K0706, low dose	K0706, high dose	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	164	162	161	
Units: NA	105	64	103	

Statistical analyses

No statistical analyses for this end point

Secondary: Level of K0706

End point title	Level of K0706
End point description:	
Data not captured	
End point type	Secondary
End point timeframe:	
Week 40	

End point values	K0706, low dose	K0706, high dose	Placebo	K0706, low dose
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[9]	0 ^[10]	0 ^[11]	0 ^[12]
Units: NA				

Notes:

[9] - Data not captured

[10] - Data not captured

[11] - Data not captured

[12] - Data not captured

End point values	K0706, high dose	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[13]	0 ^[14]		
Units: NA				

Notes:

[13] - Data not captured

[14] - Data not captured

Statistical analyses

No statistical analyses for this end point

Secondary: Exploratory Outcome: Effect of K0706 on Dopamine Cell Health in Parkinson's Disease as Detected Via Dopamine Transporter Single Photon Emission Computed Tomography (DaT SPECT) Brain Imaging

End point title	Exploratory Outcome: Effect of K0706 on Dopamine Cell Health in Parkinson's Disease as Detected Via Dopamine Transporter Single Photon Emission Computed Tomography (DaT SPECT) Brain Imaging
End point description:	
Data not captured	
End point type	Secondary
End point timeframe:	
Week 40	

End point values	K0706, low dose	K0706, high dose	Placebo	K0706, low dose
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[15]	0 ^[16]	0 ^[17]	0 ^[18]
Units: NA				

Notes:

[15] - Data not captured

[16] - Data not captured

[17] - Data not captured

[18] - Data not captured

End point values	K0706, high dose	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[19]	0 ^[20]		
Units: NA				

Notes:

[19] - Data not captured

[20] - Data not captured

Statistical analyses

No statistical analyses for this end point

Secondary: CSF K0706 Levels Progression or Target Engagement of K0706.

End point title	CSF K0706 Levels Progression or Target Engagement of K0706.
End point description:	
Data not captured	
End point type	Secondary
End point timeframe:	
Week 40	

End point values	K0706, low dose	K0706, high dose	Placebo	K0706, low dose
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[21]	0 ^[22]	0 ^[23]	0 ^[24]
Units: NA				

Notes:

[21] - Data not captured

[22] - Data not captured

[23] - Data not captured

[24] - Data not captured

End point values	K0706, high dose	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[25]	0 ^[26]		
Units: NA				

Notes:

[25] - Data not captured

[26] - Data not captured

Statistical analyses

No statistical analyses for this end point

Secondary: Brain DaT SPECT - an Imaging Tool That is a Marker of Dopaminergic Cell Health.

End point title	Brain DaT SPECT - an Imaging Tool That is a Marker of Dopaminergic Cell Health.
End point description:	
Data not captured	
End point type	Secondary
End point timeframe:	
Week 40	

End point values	K0706, low dose	K0706, high dose	Placebo	K0706, low dose
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[27]	0 ^[28]	0 ^[29]	0 ^[30]
Units: NA				

Notes:

[27] - Data not captured

[28] - Data not captured

[29] - Data not captured

[30] - Data not captured

End point values	K0706, high dose	Placebo		
------------------	------------------	---------	--	--

Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[31]	0 ^[32]		
Units: NA				

Notes:

[31] - Data not captured

[32] - Data not captured

Statistical analyses

No statistical analyses for this end point

Secondary: Blood K0706 Levels

End point title	Blood K0706 Levels
End point description:	
Data not captured	
End point type	Secondary
End point timeframe:	
Week 40	

End point values	K0706, low dose	K0706, high dose	Placebo	K0706, low dose
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[33]	0 ^[34]	0 ^[35]	0 ^[36]
Units: NA				

Notes:

[33] - Data not captured

[34] - Data not captured

[35] - Data not captured

[36] - Data not captured

End point values	K0706, high dose	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[37]	0 ^[38]		
Units: NA				

Notes:

[37] - Data not captured

[38] - Data not captured

Statistical analyses

No statistical analyses for this end point

Secondary: Skin Punch Biopsy

End point title	Skin Punch Biopsy
End point description:	
Data not captured	
End point type	Secondary
End point timeframe:	
Week 40	

End point values	K0706, low dose	K0706, high dose	Placebo	K0706, low dose
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[39]	0 ^[40]	0 ^[41]	0 ^[42]
Units: NA				

Notes:

[39] - Data not captured

[40] - Data not captured

[41] - Data not captured

[42] - Data not captured

End point values	K0706, high dose	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[43]	0 ^[44]		
Units: NA				

Notes:

[43] - Data not captured

[44] - Data not captured

Statistical analyses

No statistical analyses for this end point

Secondary: Part 1: Change From Baseline to Week 40 in the Sum of the MDS-UPDRS Parts II and III Total Scores Part 2: Change From Week 40 to Week 76 in the Sum of the MDS-UPDRS Part III Scores

End point title	Part 1: Change From Baseline to Week 40 in the Sum of the MDS-UPDRS Parts II and III Total Scores Part 2: Change From Week 40 to Week 76 in the Sum of the MDS-UPDRS Part III Scores
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Part 2: Week 76

End point values	K0706, low dose	K0706, high dose	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	30	18	25	
Units: Score on a scale				
arithmetic mean (standard deviation)				
Tremor Subscore	0.4 (± 1.87)	-0.9 (± 2.54)	-0.4 (± 2.68)	
Bradykinesia Subscore	-0.7 (± 2.25)	-0.1 (± 0.83)	0.0 (± 2.20)	
Rigidity Subscore	1.7 (± 4.46)	0.2 (± 3.81)	0.8 (± 4.12)	
Axial Symptoms Subscore	0.5 (± 1.22)	0.4 (± 1.15)	0.0 (± 1.37)	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Treatment-related TEAEs that occurred more than 30 days after the last dose date are included for reporting

Adverse event reporting additional description:

Multiple instances of occurrence of the same AE in the same patient will be considered as a single instance.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23
--------------------	----

Reporting groups

Reporting group title	Part 1: K0706 low-dose
-----------------------	------------------------

Reporting group description:

Multiple instances of occurrence of the same AE in the same patient will be considered as a single instance.

Reporting group title	Part 1: K0706 high-dose
-----------------------	-------------------------

Reporting group description:

Multiple instances of occurrence of the same AE in the same patient will be considered as a single instance.

Reporting group title	Part 1: Placebo
-----------------------	-----------------

Reporting group description:

Part 1; Multiple instances of occurrence of the same AE in the same patient will be considered as a single instance.

Reporting group title	Part 2: K0706 low-dose
-----------------------	------------------------

Reporting group description:

Part 2; Multiple instances of occurrence of the same AE in the same patient will be considered as a single instance.

Reporting group title	Part 2: K0706 high-dose
-----------------------	-------------------------

Reporting group description:

Multiple instances of occurrence of the same AE in the same patient will be considered as a single instance.

Reporting group title	Part 2: Placebo
-----------------------	-----------------

Reporting group description:

Multiple instances of occurrence of the same AE in the same patient will be considered as a single instance; part 2: Prior Placebo transitioned to K0706 High Dose

Serious adverse events	Part 1: K0706 low-dose	Part 1: K0706 high-dose	Part 1: Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 171 (1.17%)	7 / 173 (4.05%)	5 / 167 (2.99%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Femur fracture	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		

subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Coronary artery disease	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Parkinsonism	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Idiopathic Intracranial Hypertension	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastrointestinal perforation	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychotic disorder	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		

subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part 2: K0706 low-dose	Part 2: K0706 high-dose	Part 2: Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 72 (4.17%)	2 / 67 (2.99%)	4 / 77 (5.19%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Femur fracture	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Coronary artery disease	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	1 / 72 (1.39%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Parkinsonism	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Idiopathic Intracranial Hypertension	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Gastrointestinal perforation	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		

subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Delirium	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychotic disorder	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Part 1: K0706 low-dose	Part 1: K0706 high-dose	Part 1: Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	80 / 171 (46.78%)	114 / 173 (65.90%)	48 / 167 (28.74%)
Vascular disorders			
Flushing			
subjects affected / exposed	2 / 171 (1.17%)	4 / 173 (2.31%)	0 / 167 (0.00%)
occurrences (all)	2	4	0
Hypotension			
subjects affected / exposed	1 / 171 (0.58%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	1	1	0
Raynaud's phenomenon			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Hypertension			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Peripheral swelling			
subjects affected / exposed	2 / 171 (1.17%)	1 / 173 (0.58%)	1 / 167 (0.60%)
occurrences (all)	3	1	1

Chest pain			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	0	1
Early satiety			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Face oedema			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
General physical health deterioration			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	0	1
Oedema peripheral			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Pain			
subjects affected / exposed	0 / 171 (0.00%)	4 / 173 (2.31%)	2 / 167 (1.20%)
occurrences (all)	0	5	2
Chest discomfort			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Chills			
subjects affected / exposed	0 / 171 (0.00%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	0	2	0
Facial pain			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Mucosal dryness			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Asthenia			
subjects affected / exposed	1 / 171 (0.58%)	5 / 173 (2.89%)	0 / 167 (0.00%)
occurrences (all)	1	5	0
Immune system disorders			
Hypersensitivity			

subjects affected / exposed occurrences (all)	1 / 171 (0.58%) 2	0 / 173 (0.00%) 0	0 / 167 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Nasal congestion			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Pleural effusion			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Pulmonary mass			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Cough			
subjects affected / exposed	1 / 171 (0.58%)	3 / 173 (1.73%)	0 / 167 (0.00%)
occurrences (all)	1	3	0
Aphonia			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Throat irritation			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	1 / 167 (0.60%)
occurrences (all)	0	1	1
Psychiatric disorders			
Depressed mood			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	0	1
Affect lability			

subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	0	1
Irritability			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Mood altered	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Nightmare			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Anxiety			
subjects affected / exposed	0 / 171 (0.00%)	3 / 173 (1.73%)	1 / 167 (0.60%)
occurrences (all)	0	3	2
Hallucination, visual			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Depression			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	1 / 167 (0.60%)
occurrences (all)	0	1	1
Agitation			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Impulse-control disorder			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	2 / 171 (1.17%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	2	2	0
Abnormal dreams			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Affective disorder			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Persistent depressive disorder			

subjects affected / exposed occurrences (all)	0 / 171 (0.00%) 0	1 / 173 (0.58%) 1	0 / 167 (0.00%) 0
Investigations			
Liver function test increased subjects affected / exposed occurrences (all)	1 / 171 (0.58%) 1	0 / 173 (0.00%) 0	0 / 167 (0.00%) 0
Mean platelet volume decreased subjects affected / exposed occurrences (all)	1 / 171 (0.58%) 1	0 / 173 (0.00%) 0	0 / 167 (0.00%) 0
Platelet count increased subjects affected / exposed occurrences (all)	1 / 171 (0.58%) 1	0 / 173 (0.00%) 0	0 / 167 (0.00%) 0
Protein total increased subjects affected / exposed occurrences (all)	1 / 171 (0.58%) 1	0 / 173 (0.00%) 0	0 / 167 (0.00%) 0
Prothrombin time prolonged subjects affected / exposed occurrences (all)	1 / 171 (0.58%) 1	0 / 173 (0.00%) 0	0 / 167 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 171 (0.58%) 1	3 / 173 (1.73%) 3	1 / 167 (0.60%) 2
Weight decreased subjects affected / exposed occurrences (all)	2 / 171 (1.17%) 2	1 / 173 (0.58%) 1	0 / 167 (0.00%) 0
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 171 (0.00%) 0	1 / 173 (0.58%) 1	0 / 167 (0.00%) 0
Heart rate irregular subjects affected / exposed occurrences (all)	0 / 171 (0.00%) 0	0 / 173 (0.00%) 0	0 / 167 (0.00%) 0
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	1 / 171 (0.58%) 1	0 / 173 (0.00%) 0	0 / 167 (0.00%) 0
Cardiac disorders			

Palpitations			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Atrial fibrillation			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	0	1
Bradycardia			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	0	1
Nervous system disorders			
Hypoaesthesia			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Lethargy			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	1	0	1
Dysaesthesia			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Memory impairment			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	0	1
Neurological symptom			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	2 / 167 (1.20%)
occurrences (all)	0	0	2
Headache	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	6 / 171 (3.51%)	5 / 173 (2.89%)	5 / 167 (2.99%)
occurrences (all)	6	5	6
Sciatica			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Paraesthesia			
subjects affected / exposed	1 / 171 (0.58%)	1 / 173 (0.58%)	1 / 167 (0.60%)
occurrences (all)	1	1	1
Dysgeusia			

subjects affected / exposed	2 / 171 (1.17%)	1 / 173 (0.58%)	3 / 167 (1.80%)
occurrences (all)	2	1	4
Migraine			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	2 / 171 (1.17%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	2	0	1
Speech disorder			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Taste disorder			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Dizziness	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	2 / 171 (1.17%)	8 / 173 (4.62%)	4 / 167 (2.40%)
occurrences (all)	2	9	6
Tremor	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	2 / 171 (1.17%)	8 / 173 (4.62%)	1 / 167 (0.60%)
occurrences (all)	2	8	1
Burning sensation			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Cognitive disorder			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Syncope			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 171 (0.00%)	3 / 173 (1.73%)	1 / 167 (0.60%)
occurrences (all)	0	3	1
Leukopenia	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0

Neutropenia			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Thrombocytosis			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Eye disorders			
Optic neuropathy			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Ocular hyperaemia			
subjects affected / exposed	0 / 171 (0.00%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	0	2	0
Visual acuity reduced transiently			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	0	1
Papilloedema			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Visual impairment			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	3 / 167 (1.80%)
occurrences (all)	0	0	3
Eye swelling	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 171 (0.00%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	0	2	0
Swelling of eyelid			
subjects affected / exposed	0 / 171 (0.00%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	0	2	0
Xerophthalmia			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			

Constipation	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 171 (0.00%)	5 / 173 (2.89%)	1 / 167 (0.60%)
occurrences (all)	0	5	1
Gastroesophageal reflux			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	2	0	1
Haemorrhoids			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Anal incontinence			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Faeces soft			
subjects affected / exposed	2 / 171 (1.17%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	2	0	0
Hiccups			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Lip oedema			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Oral dysaesthesia			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Tongue pruritus			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	0	1
Ulcerative gastritis			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Diarrhoea	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	13 / 171 (7.60%)	13 / 173 (7.51%)	2 / 167 (1.20%)
occurrences (all)	13	21	3
Abdominal pain upper	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	2 / 171 (1.17%)	5 / 173 (2.89%)	1 / 167 (0.60%)
occurrences (all)	3	6	2

Dry mouth			
subjects affected / exposed	1 / 171 (0.58%)	1 / 173 (0.58%)	2 / 167 (1.20%)
occurrences (all)	1	1	2
Nausea			
subjects affected / exposed	13 / 171 (7.60%)	14 / 173 (8.09%)	6 / 167 (3.59%)
occurrences (all)	14	17	6
Gastrointestinal disorder			
subjects affected / exposed	1 / 171 (0.58%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	1	3	0
Gastritis			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Abdominal distension			
subjects affected / exposed	3 / 171 (1.75%)	2 / 173 (1.16%)	1 / 167 (0.60%)
occurrences (all)	3	2	1
Abdominal pain	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	4 / 171 (2.34%)	5 / 173 (2.89%)	1 / 167 (0.60%)
occurrences (all)	4	7	1
Dyspepsia			
subjects affected / exposed	3 / 171 (1.75%)	0 / 173 (0.00%)	2 / 167 (1.20%)
occurrences (all)	4	0	2
Gastric disorder			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Gastritis erosive			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Glossitis			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	2	0
Abdominal discomfort			
subjects affected / exposed	0 / 171 (0.00%)	5 / 173 (2.89%)	1 / 167 (0.60%)
occurrences (all)	0	6	1
Vomiting			
subjects affected / exposed	0 / 171 (0.00%)	6 / 173 (3.47%)	1 / 167 (0.60%)
occurrences (all)	0	7	1

Flatulence			
subjects affected / exposed	3 / 171 (1.75%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	3	2	0
Eructation			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Lip swelling			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Rectal tenesmus			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Defaecation urgency			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Infrequent bowel movements			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			
Hepatitis			
subjects affected / exposed	0 / 171 (0.00%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	0	2	0
Skin and subcutaneous tissue disorders			
Butterfly rash			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Rash macular			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Rash	Additional description: For Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	18 / 171 (10.53%)	27 / 173 (15.61%)	3 / 167 (1.80%)
occurrences (all)	23	30	3
Pruritus			
subjects affected / exposed	8 / 171 (4.68%)	11 / 173 (6.36%)	2 / 167 (1.20%)
occurrences (all)	9	13	2
Rash papular			

subjects affected / exposed	1 / 171 (0.58%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	1	3	0
Mucocutaneous rash			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	1 / 171 (0.58%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	1	2	0
Night sweats			
subjects affected / exposed	1 / 171 (0.58%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	1	1	0
Erythema	Additional description: For Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	7 / 171 (4.09%)	17 / 173 (9.83%)	0 / 167 (0.00%)
occurrences (all)	10	18	0
Alopecia			
subjects affected / exposed	4 / 171 (2.34%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	4	3	0
Dermatitis allergic			
subjects affected / exposed	0 / 171 (0.00%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	0	2	0
Hyperhidrosis			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Madarosis			
subjects affected / exposed	3 / 171 (1.75%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	3	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 171 (0.00%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	0	2	0
Keratosis pilaris			
subjects affected / exposed	1 / 171 (0.58%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	1	1	0
Photosensitivity reaction			
subjects affected / exposed	1 / 171 (0.58%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	1	1	0
Rash pruritic			

subjects affected / exposed	0 / 171 (0.00%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	0	2	0
Erythema multiforme			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Skin depigmentation			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Skin exfoliation			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Skin reaction			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Sunburn			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			
Micturition urgency			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Calculus bladder			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Urinary hesitation			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	1 / 167 (0.60%)
occurrences (all)	0	0	1
Flank pain			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Muscle spasms			
subjects affected / exposed	0 / 171 (0.00%)	6 / 173 (3.47%)	0 / 167 (0.00%)
occurrences (all)	0	6	0
Myalgia			
subjects affected / exposed	2 / 171 (1.17%)	3 / 173 (1.73%)	0 / 167 (0.00%)
occurrences (all)	2	3	0
Pain in extremity			
subjects affected / exposed	0 / 171 (0.00%)	2 / 173 (1.16%)	1 / 167 (0.60%)
occurrences (all)	0	2	1
Musculoskeletal stiffness			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Muscle rigidity			
subjects affected / exposed	0 / 171 (0.00%)	1 / 173 (0.58%)	0 / 167 (0.00%)
occurrences (all)	0	1	0
Back pain			
subjects affected / exposed	2 / 171 (1.17%)	2 / 173 (1.16%)	0 / 167 (0.00%)
occurrences (all)	3	2	0
Infections and infestations			
Pharyngitis			
subjects affected / exposed	1 / 171 (0.58%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	3 / 171 (1.75%)	4 / 173 (2.31%)	5 / 167 (2.99%)
occurrences (all)	4	4	7
Upper respiratory tract infection			
subjects affected / exposed	0 / 171 (0.00%)	0 / 173 (0.00%)	0 / 167 (0.00%)
occurrences (all)	0	0	0
Folliculitis			

subjects affected / exposed occurrences (all)	0 / 171 (0.00%) 0	1 / 173 (0.58%) 1	0 / 167 (0.00%) 0
Influenza	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed occurrences (all)	2 / 171 (1.17%) 2	0 / 173 (0.00%) 0	0 / 167 (0.00%) 0
Metabolism and nutrition disorders			
Increased appetite			
subjects affected / exposed occurrences (all)	0 / 171 (0.00%) 0	0 / 173 (0.00%) 0	2 / 167 (1.20%) 2
Vitamin D deficiency			
subjects affected / exposed occurrences (all)	1 / 171 (0.58%) 1	0 / 173 (0.00%) 0	0 / 167 (0.00%) 0
Decreased appetite			
subjects affected / exposed occurrences (all)	0 / 171 (0.00%) 0	6 / 173 (3.47%) 6	0 / 167 (0.00%) 0
Hyperglycaemia			
subjects affected / exposed occurrences (all)	0 / 171 (0.00%) 0	0 / 173 (0.00%) 0	1 / 167 (0.60%) 1
Metabolic acidosis			
subjects affected / exposed occurrences (all)	0 / 171 (0.00%) 0	0 / 173 (0.00%) 0	0 / 167 (0.00%) 0

Non-serious adverse events	Part 2: K0706 low-dose	Part 2: K0706 high-dose	Part 2: Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 72 (11.11%)	46 / 67 (68.66%)	0 / 77 (0.00%)
Vascular disorders			
Flushing			
subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Hypotension			
subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Raynaud's phenomenon			
subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Hypertension			

subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Peripheral swelling			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Chest pain			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Early satiety			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	1 / 72 (1.39%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	1	1	0
Chest discomfort			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Chills			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Mucosal dryness			

subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Asthenia			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Nasal congestion			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Pleural effusion			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Pulmonary mass			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Aphonia			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Dyspnoea			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Throat irritation			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Rhinorrhoea			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Epistaxis			

subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Psychiatric disorders			
Depressed mood			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Affect lability			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Irritability			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Mood altered	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Nightmare			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Hallucination, visual			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Agitation			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Impulse-control disorder			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Insomnia			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0

Abnormal dreams subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Affective disorder subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Persistent depressive disorder subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Investigations			
Liver function test increased subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	1 / 67 (1.49%) 1	0 / 77 (0.00%) 0
Mean platelet volume decreased subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Platelet count increased subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Protein total increased subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Prothrombin time prolonged subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 72 (1.39%) 1	2 / 67 (2.99%) 2	0 / 77 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	1 / 67 (1.49%) 1	0 / 77 (0.00%) 0
Heart rate irregular			

subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	1 / 67 (1.49%) 1	0 / 77 (0.00%) 0
Injury, poisoning and procedural complications Fall subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all) Atrial fibrillation subjects affected / exposed occurrences (all) Bradycardia subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0 0 / 72 (0.00%) 0 0 / 72 (0.00%) 0	0 / 67 (0.00%) 0 0 / 67 (0.00%) 0 0 / 67 (0.00%) 0	0 / 77 (0.00%) 0 0 / 77 (0.00%) 0 0 / 77 (0.00%) 0
Nervous system disorders Hypoaesthesia subjects affected / exposed occurrences (all) Lethargy subjects affected / exposed occurrences (all) Dysaesthesia subjects affected / exposed occurrences (all) Memory impairment subjects affected / exposed occurrences (all) Neurological symptom subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0 0 / 72 (0.00%) 0 0 / 72 (0.00%) 0 0 / 72 (0.00%) 0 0 / 72 (0.00%) 0	0 / 67 (0.00%) 0 0 / 67 (0.00%) 0 0 / 67 (0.00%) 0 0 / 67 (0.00%) 0	0 / 77 (0.00%) 0 0 / 77 (0.00%) 0 0 / 77 (0.00%) 0 0 / 77 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
	1 / 72 (1.39%) 1	3 / 67 (4.48%) 3	0 / 77 (0.00%) 0
Sciatica			

subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Somnolence			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Speech disorder			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Dizziness	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	2	0
Tremor	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	3 / 67 (4.48%)	0 / 77 (0.00%)
occurrences (all)	0	3	0
Burning sensation			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Cognitive disorder			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Leukopenia	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	1 / 72 (1.39%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	1	1	0
Neutropenia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Thrombocytosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Optic neuropathy			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced transiently			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Papilloedema			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	1 / 72 (1.39%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	1	1	0
Eye swelling	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Swelling of eyelid			

subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Xerophthalmia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Constipation	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	2 / 67 (2.99%)	0 / 77 (0.00%)
occurrences (all)	0	2	0
Gastroesophageal reflux			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 72 (0.00%)	2 / 67 (2.99%)	0 / 77 (0.00%)
occurrences (all)	0	2	0
Anal incontinence			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Faeces soft			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Lip oedema			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Oral dysaesthesia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Tongue pruritus			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Ulcerative gastritis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0

Diarrhoea subjects affected / exposed occurrences (all)	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
	1 / 72 (1.39%) 1	3 / 67 (4.48%) 3	0 / 77 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
	0 / 72 (0.00%) 0	4 / 67 (5.97%) 4	0 / 77 (0.00%) 0
Dry mouth subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	2 / 72 (2.78%) 2	3 / 67 (4.48%) 3	0 / 77 (0.00%) 0
Gastrointestinal disorder subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	3 / 67 (4.48%) 3	0 / 77 (0.00%) 0
Gastritis subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Abdominal distension subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose		
	0 / 72 (0.00%) 0	1 / 67 (1.49%) 1	0 / 77 (0.00%) 0
Dyspepsia subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Gastric disorder subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Gastritis erosive subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	1 / 67 (1.49%) 1	0 / 77 (0.00%) 0
Glossitis subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0

Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Flatulence subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Eructation subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Lip swelling subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Rectal tenesmus subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Defaecation urgency subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Infrequent bowel movements subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Hepatobiliary disorders Hepatitis subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Skin and subcutaneous tissue disorders Butterfly rash subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Rash macular subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	2 / 67 (2.99%) 2	0 / 77 (0.00%) 0
Rash	Additional description: For Part 2: Prior Placebo transitioned to K0706 High Dose		

subjects affected / exposed	0 / 72 (0.00%)	7 / 67 (10.45%)	0 / 77 (0.00%)
occurrences (all)	0	9	0
Pruritus			
subjects affected / exposed	0 / 72 (0.00%)	2 / 67 (2.99%)	0 / 77 (0.00%)
occurrences (all)	0	2	0
Rash papular			
subjects affected / exposed	0 / 72 (0.00%)	2 / 67 (2.99%)	0 / 77 (0.00%)
occurrences (all)	0	2	0
Mucocutaneous rash			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Urticaria			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Erythema	Additional description: For Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	7 / 67 (10.45%)	0 / 77 (0.00%)
occurrences (all)	0	8	0
Alopecia			
subjects affected / exposed	0 / 72 (0.00%)	3 / 67 (4.48%)	0 / 77 (0.00%)
occurrences (all)	0	5	0
Dermatitis allergic			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Madarosis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Keratosis pilaris			

subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Photosensitivity reaction			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Erythema multiforme			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Skin depigmentation			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Skin exfoliation			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Skin reaction			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Sunburn			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Micturition urgency			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Calculus bladder			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Urinary hesitation			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0

Pollakiuria subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Flank pain subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	1 / 67 (1.49%) 1	0 / 77 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	1 / 67 (1.49%) 1	0 / 77 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	1 / 67 (1.49%) 1	0 / 77 (0.00%) 0
Musculoskeletal stiffness subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	1 / 67 (1.49%) 1	0 / 77 (0.00%) 0
Muscle rigidity subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	2 / 67 (2.99%) 2	0 / 77 (0.00%) 0
Infections and infestations			
Pharyngitis subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	0 / 67 (0.00%) 0	0 / 77 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 72 (0.00%) 0	4 / 67 (5.97%) 4	0 / 77 (0.00%) 0
Upper respiratory tract infection			

Additional description: For part 2: Prior Placebo transitioned to K0706 High Dose

subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0
Folliculitis			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Influenza	Additional description: Part 2: Prior Placebo transitioned to K0706 High Dose		
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Increased appetite			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 72 (0.00%)	0 / 67 (0.00%)	0 / 77 (0.00%)
occurrences (all)	0	0	0
Metabolic acidosis			
subjects affected / exposed	0 / 72 (0.00%)	1 / 67 (1.49%)	0 / 77 (0.00%)
occurrences (all)	0	1	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
30 September 2019	The protocol was amended due to the following reasons: (a.) Addition of new formulation: Powder for suspension (b.) Addition of new doses: 192 mg powder (low dose) and 384 mg powder (high dose)
20 July 2021	The study was amended because the study design was changed to add an optional long-term extension study.
23 October 2023	The protocol was amended because the primary endpoint was modified.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported